BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30161074)

  • 1. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma.
    Nakagawa S; Yamashita YI; Umezaki N; Yamao T; Okabe H; Imai K; Nitta H; Hashimoto D; Chikamoto A; Baba H
    Pancreas; 2018 Oct; 47(9):1130-1134. PubMed ID: 30161074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma.
    Abe T; Nakata K; Kibe S; Mori Y; Miyasaka Y; Ohuchida K; Ohtsuka T; Oda Y; Nakamura M
    Ann Surg Oncol; 2018 Dec; 25(13):3996-4003. PubMed ID: 30225838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
    Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the physiobiological parameter-based grading system for predicting the long-term prognosis after curative surgery for resectable pancreatic cancer.
    Abe T; Amano H; Kobayashi T; Hattori M; Hanada K; Nakahara M; Ohdan H; Noriyuki T
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):613-619. PubMed ID: 32978015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
    Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma.
    Lee W; Yoon YS; Han HS; Cho JY; Choi Y; Jang JY; Choi H
    J Surg Oncol; 2016 Feb; 113(2):203-8. PubMed ID: 26799261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma.
    Crippa S; Pergolini I; Javed AA; Honselmann KC; Weiss MJ; Di Salvo F; Burkhart R; Zamboni G; Belfiori G; Ferrone CR; Rubini C; Yu J; Gasparini G; Qadan M; He J; Lillemoe KD; Castillo CF; Wolfgang CL; Falconi M
    Ann Surg; 2022 Aug; 276(2):378-385. PubMed ID: 33086324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study.
    Itoh S; Tsujita E; Fukuzawa K; Sugimachi K; Iguchi T; Ninomiya M; Maeda T; Kajiyama K; Adachi E; Uchiyama H; Utsunomiya T; Ikeda Y; Maekawa S; Toshima T; Harada N; Yoshizumi T; Mori M
    Pancreatology; 2021 Oct; 21(7):1356-1363. PubMed ID: 34426076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
    Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
    Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic nutritional index as a predictor of survival in resectable gastric cancer patients with normal preoperative serum carcinoembryonic antigen levels: a propensity score matching analysis.
    Hirahara N; Tajima Y; Fujii Y; Kaji S; Yamamoto T; Hyakudomi R; Taniura T; Kawabata Y
    BMC Cancer; 2018 Mar; 18(1):285. PubMed ID: 29534689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
    Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.